52 Week Range
As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Hansoh Pharmaceutical Group Gets Drug Registration Approval For Its "Tanneng" Product
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED is a China-based investment holding company principally involved in the the research and development, production and sale of pharmaceutical products. The Company’s main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The Company’s products are mainly used for central nervous system disease, oncology, anti-infection, diabetes, digestive tract and cardiovascular treatment. The Company distributes its products in domestic market.
Biotechnology & Drugs
9 Dongjin Road
Economic & Technical Development Zone
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Scepticism over AB InBev's high valuations doomed Budweiser APAC's IPO of up to $9.8 billion - poised to be the world's biggest this year - investors and bankers said, putting would-be floats on notice that careful pricing remains key to success.
By Julie Zhu, Joshua Franklin, Abhinav Ramnarayan and Philip Blenkinsop
Asia's army of equity capital bankers are betting on a stream of listed companies seeking fresh funds, including Alibaba's plans for an up to $20 billion Hong Kong share sale, as trade tensions continue to weigh on the big business of taking firms public.
Goldman Sachs has hired Samuel Thong from Morgan Stanley as the chairman of the healthcare group in the bank's Asia excluding-Japan investment banking division, people with knowledge of the move said.
China's pharma shake-up has won a healthy endorsement. Drugmaker Hansoh Pharmaceutical <3692.HK> will go public this week after raising funds at a $10.3 billion valuation in its Hong Kong initial public offering. That suggests that Beijing’s radical price reforms will produce...
* Shares were being sold in indicative band of HK$13.06-HK$14.26
Drugmaker Hansoh Pharmaceutical Group on Wednesday priced its Hong Kong initial public offering at the top end of its targeted range, two people with direct knowledge of the matter said, raising roughly $1 billion.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.